Marker Therapeutics Inc (MRKR)

[BluMarlin1960]

Exactly, well put, different Cancer, different application.

TPIV has multiple platforms for multiple cancers, Ovarian and TNBC where there are little no promising treatments marketed at this point in time, that do not have serious side effects.

TPIV has purposely targeted Ovarian, TNBC and HER2NUE [better than Herceptin?] just for those reasons, and even if we are behind the industry [timeline wise] if TPIV has a vaccine that treats a broader application of people, at a much, much cheaper cost, with little side effects.

Whoever is at the party, or on their way will have to better that platform, or TPIV will emerge as the optimum treatment.

BLU